Clinical presentation, treatment patterns, and outcomes of colorectal cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia: A prospective cohort study

被引:4
|
作者
Zingeta, Girum Tessema [1 ]
Worku, Yohannes T. [1 ]
Getachew, Assefa [2 ]
Feyisa, Jilcha Diribi [1 ,3 ]
Furgassa, Hawi [1 ,3 ]
Belay, Winini [4 ]
Mengesha, Tariku [5 ]
Jemal, Ahmedin [6 ]
Assefa, Mathewos [1 ]
机构
[1] Addis Ababa Univ, Sch Med, Dept Oncol, Addis Ababa, Ethiopia
[2] Addis Ababa Univ, Sch Med, Dept Radiol, Addis Ababa, Ethiopia
[3] St Paul Hosp Millennium Med Coll, Dept Oncol, Addis Ababa, Ethiopia
[4] Addis Ababa Univ, Sch Publ Hlth, Dept Reprod Hlth & Hlth Serv Management, Addis Ababa, Ethiopia
[5] St Peter Specialized Hosp, Dept Epidemiol, Addis Ababa, Ethiopia
[6] Amer Canc Soc, Dept Surveillance & Hlth Serv Res, Atlanta, GA USA
关键词
colorectal cancer; Ethiopia; survival; treatment pattern; SURVIVAL; TIME; GUIDELINES;
D O I
10.1002/cnr2.1869
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundColorectal cancer (CRC) is the third most common cause of cancer death in both genders worldwide. AimsThis study aimed to evaluate the outcomes and prognostic factors of CRC patients at Tikur Anbessa Specialized Hospital in Ethiopia. Methods and ResultsA prospective cohort study was conducted on 209 patients from January 2020 to September 2022. Kaplan-Meier curves and bivariate and multivariate Cox regression analyses were used to analyze overall and progression-free survival, with a significance value of P < .05. Results showed an overall mortality rate was 67.46% (95% confidence interval [CI]: 61.0-74.0), while the 1-year overall survival (OS) rate was 63.16% (95% CI: 56.23-69.29), with a median follow-up duration of 20 months. The median OS and progression-free survival times were 17 and 11 months, respectively. Age above 40 years (hazard ratio [HR] = 1.53, 1.02-2.29, p < .040), lower educational level (high school and below) (HR = 2.20, 1.24-3.90, p < .007), poor performance status (HR = 1.60, 1.03-2.48, p < .035), Hgb & LE;12.5 g/dL (HR = 1.55, 1.03-2.08, p < .035), T-4 disease (HR = 6.05, 2.28-16.02, p < .000), and metastases at diagnosis (HR = 8.53, 3.77-19.25, p < .000) were all associated with poorer survival. ConclusionThese findings suggest that poor survival of CRC patients in Ethiopia is largely due to advanced stage of the disease and lack of timely treatment, and highlight the urgent need for improved access to cancer treatment in the region.
引用
收藏
页数:14
相关论文
共 50 条